A retrospective, multi-center, single-blind, pivotal trial to assess clinical equivalence with stage II and III advanced gastric cancer based on the 6th and 8th of the AJCC

The safety and effectiveness of nProfiler® 1 Stomach Cancer Assay have been evaluated with stage II and III advanced gastric cancer patients based on the 6th of the American Joint Committee on Cancer (AJCC) through discovery clinical trial (418 patients) and confirmatory clinical trial (684 patients).

The goal of this study, a retrospective, multi-center, single-blind, pivotal trial, is to assess clinical equivalence with stage II and III advanced gastric cancer based on the 6th and 8th of the AJCC and to evaluate prognostic equivalence between surgery only group and adjuvant chemotherapy group in Low risk group.

The study will follow these procedures; Sample screening, Sample Preparation and Sample Criteria Evaluation, Sample enrollment, nProfiler® 1 Stomach Cancer Assay (gastric cancer prognosis prediction), Prognostic Result Report, and Evaluation of Clinical Performance.

Inclusion Criteria:

1. Sample providers criteria

   • Male and female adult patients aged 19 years or over
   • Postoperative patients with gastric cancer invading the submucosal layer and having 3 or more lymph nodes metastasis or who with gastric cancer infiltration of muscularis propria and lymph node metastasis (stage II and III advanced gastric cancer patients, 8th of the AJCC)
   • Patients who have not received neoadjuvant chemotherapy and radiotherapy
   • Patients with pathological record and clinical information after surgery from archived FFPE(formalin-fixed paraffin-embedded) samples between 2005 and 2010
   • Patients who have not been included in discovery clinical trial and confirmatory clinical trial
   • Patients who have undergone a radical gastrectomy and who show no evidence of residual tumors as observed with the unaided eye or through a microscope

2. Sample criteria

   • The FFPE tumor specimens in storage have a tumor amount of at least 20% and therefore can be tested.
   • The quantity (not less than 400ng) and quality (A260/280 of not less than 1.8) of RNA are sufficient for analysis.

Exclusion Criteria:

1. Sample providers criteria

   • Male and female patients aged less than 19 years
   • Postoperative patients with gastric cancer invading the mucosa and submucosal layer and having less than 3 lymph nodes metastasis or who with gastric cancer infiltration of muscularis propria without lymph node metastasis (stage II and III advanced gastric cancer patients, 8th of the AJCC)
   • Patients who have received neoadjuvant chemotherapy or radiotherapy
   • Patients without pathological record and clinical information after surgery from archived FFPE samples between 2005 and 2010
   • Patients who have been included in discovery clinical trial and confirmatory clinical trial
   • Patients with residual tumors after surgery

2. Sample criteria

   • The FFPE tumor specimens in storage have a tumor amount of less than 20% and therefore cannot be tested
   • The quantity and quality of RNA are not sufficient for analysis

19 years or older patients with stage II, III gastric adenocarcinoma